Parvovirus B19: Difference between revisions
(added management) |
|||
| Line 15: | Line 15: | ||
==Management== | ==Management== | ||
*Parvovirus is usually self-limiting and requires no further treatment. | *Parvovirus is usually self-limiting and requires no further treatment. | ||
*Management should be targeted at reducing symptoms, such as using anti-inflammatory medications for arthropathy or performing transfusions for aplastic anemia. | |||
==Disposition== | ==Disposition== | ||
Revision as of 12:32, 29 February 2016
Background
- In children: causes Erythema infectiosum (Fifth disease)
- In transplant patients on immunosuppressive drugs: causes RBC aplasia.
- Short-lived, may not be discovered
- Parvovirus only replicated in erythroid progenitor cells
Clinical Features
Differential Diagnosis
Diagnosis
Management
- Parvovirus is usually self-limiting and requires no further treatment.
- Management should be targeted at reducing symptoms, such as using anti-inflammatory medications for arthropathy or performing transfusions for aplastic anemia.
Disposition
See Also
External Links
References
- Fish RM, Massad MG. The Transplant Patient. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011.
- Place R, Lagoc AT, Mayer TA, Lawlor CJ. Oncology and Hematology Emergencies in Children. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011